Drug intelligence / Profile preview

TC-255

Development stage: Unknown
Lead developer: TechnoPhage

Overview

TC-255 is a therapeutic candidate currently in the discovery stage of development by TechnoPhage, a Portuguese biopharmaceutical company. As of 2024, the specific therapeutic indication, target, and mechanism of action for TC-255 remain undisclosed by the developer. The asset is part of TechnoPhage's pipeline, which is primarily built around its proprietary bacteriophage-based technology platforms and antibody discovery capabilities. TC-255 represents one of the company's early-stage programs aimed at addressing undisclosed medical conditions.

Beyond the preview

Go deeper on TC-255.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TC-255.

Explore the full profile